12 results match your criteria: "Medica Cor Hospital[Affiliation]"
Impact of renin-angiotensin system targeted therapy on aortic elastic properties assessed by computed tomography.
Int J Cardiol Heart Vasc
December 2024
Medica Cor Hospital, 1713 Ruse, Bulgaria.
Background: Aortic stiffening is a well-known cardiovascular risk factor. Computed tomography (CT) has proven to be a valuable tool in the assessment of aortic elastic properties. Drugs that inhibit the renin-angiotensin system (RAS) play a central role in cardioprotective therapy.
View Article and Find Full Text PDFCurrent Challenges in Coronary Bifurcation Interventions.
Medicina (Kaunas)
September 2024
Medica Cor Hospital, 7013 Ruse, Bulgaria.
Article Synopsis
- Coronary bifurcation lesions are common in heart procedures but involve significant challenges, leading to higher risks and poorer outcomes for patients.
- This review discusses the unique characteristics of these lesions and the difficulties faced during treatment, while also assessing different methodologies for managing them.
- A new combined approach for treating bifurcation lesions shows promise for improving procedures and long-term results, highlighting the need for ongoing refinement and evaluation of these techniques.
Impact of the Type of Anticoagulation Therapy on Long-Term Clinical Outcomes in Patients with Coronary Bifurcation Lesion and Atrial Fibrillation-Insights from the Bulgarian Bifurcation Registry.
Medicina (Kaunas)
August 2024
National Medical Institute of Internal Affairs and Administration Ministry, 02-507 Warsaw, Poland.
Article Synopsis
- * The study included 226 patients with a mean age of 70.9 years, finding that DOAC treatment correlated with significantly lower all-cause and cardiovascular mortality compared to VKA treatment over a median follow-up of about 55 months.
- * VKA therapy was identified as an independent predictor of cardiovascular death, highlighting the advantages of using DOACs in patients with AF and coronary bifurcation lesions.
Side branch predilatation during percutaneous coronary bifurcation intervention: Long-term mortality analysis.
Kardiol Pol
May 2024
Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Ramsay Santé, Massy, France.
Article Synopsis
- Side branch predilatation (SBPD) during coronary bifurcation interventions is discouraged by current guidelines, yet there is limited data on its long-term clinical outcomes.
- This study examined the long-term mortality outcomes for patients undergoing SBPD versus those who did not, using a large patient registry and careful statistical matching.
- Results showed that patients who underwent SBPD had higher all-cause and cardiovascular mortality rates compared to those who did not, indicating that while SBPD might improve angiographic results, it does not lead to better overall survival.
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.
Diabetes Res Clin Pract
August 2023
Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna, Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum, University of Bologna, Italy. Electronic address:
Aims: To analyze the association between chronic SGLT2-I treatment and development of contrast-induced acute kidney injury (CI-AKI) in diabetic patients with acute myocardial infarction (AMI) undergoing PCI.
Methods: Multicenter international registry of consecutive patients with type 2 diabetes mellitus (T2DM) and AMI undergoing PCI between 2018 and 2021. The study population was stratified by the presence of chronic kidney disease (CKD) and anti-diabetic therapy at admission (SGLT2-I versus non-SGLT2-I users).
Reply to SGLT-2 inhibitors: Post-infarction interventional effects.
Pharmacol Res
March 2023
Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy. Electronic address:
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Pharmacol Res
January 2023
Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium. Electronic address:
Article Synopsis
- - This study aims to compare the in-hospital and long-term outcomes of Type 2 Diabetes Mellitus (T2DM) patients with acute myocardial infarction (AMI) who were treated with SGLT2 inhibitors versus those on other diabetes medications.
- - Results indicated that patients using SGLT2 inhibitors experienced significantly lower rates of in-hospital cardiovascular death, arrhythmias, and contrast-induced acute kidney injury, along with better long-term cardiovascular outcomes during a 24-month follow-up period.
- - The findings suggest that SGLT2 inhibitors could play an important role in reducing adverse cardiovascular events in T2DM patients with AMI, highlighting their potential cardioprotective effects.
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
Front Cardiovasc Med
September 2022
Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Article Synopsis
- Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) provide cardiovascular benefits and reduce the occurrence of arrhythmias in patients with and without type 2 diabetes mellitus (T2DM).
- A study analyzed T2DM patients with acute myocardial infarction (AMI) to compare the incidence of new-onset cardiac arrhythmias between those treated with SGLT2-i and those using other anti-diabetic medications.
- Results indicated that SGLT2-i users had a significantly lower rate of in-hospital new-onset cardiac arrhythmias, particularly ventricular arrhythmias, suggesting that SGLT2-i may help reduce these risks in T2DM patients during hospitalization.
A novel technique of proximal optimization with kissing balloon inflation in bifurcation lesions.
Cardiol J
December 2022
Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
Background: Percutaneous coronary interventions (PCI) of bifurcation lesions poses a technical challenge with a high complication rate. Kissing balloon inflation (KBI) and proximal optimization technique (POT) are used to correct bifurcation carina after stenting. However, both may still lead to uncomplete strut apposition to the side branch (SB) lateral wall.
View Article and Find Full Text PDFInfarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Cardiovasc Diabetol
May 2022
Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, 40138, Bologna, Italy.
Article Synopsis
- - The study investigates the anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors (SGLT2-I) in patients with acute myocardial infarction (AMI), particularly in those with type 2 diabetes, examining their impact on inflammatory markers and infarct size compared to other diabetes medications.
- - In a cohort of 583 AMI patients, those treated with SGLT2-I exhibited less hyperglycemia at admission and had smaller infarct sizes, alongside significantly lower inflammatory markers at various time points compared to patients using other oral anti-diabetic agents.
- - The findings suggest that SGLT2-I not only lowers blood sugar but also effectively reduces inflammation during AMI, making them a promising treatment option for diabetic patients